NAD+ Precursors (NMN/NR)
Precursors to NAD+, a critical coenzyme for cellular energy and longevity pathways. NAD+ levels decline with age.
What is NAD+ Precursors (NMN/NR)?
NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production, DNA repair, and sirtuin activation. NAD+ levels decline 50% between ages 40-60. Supplementation aims to restore youthful NAD+ levels and support longevity pathways. While not technically peptides, they are commonly discussed alongside peptides in the longevity community.
What NAD+ Precursors (NMN/NR) Is Investigated For
NMN and NR — which are not technically peptides but small-molecule NAD+ precursors — are used to restore the age-related decline in cellular NAD+ that drives mitochondrial dysfunction, sirtuin deficit, and impaired DNA repair, with downstream goals around energy, metabolism, and healthspan. The strongest evidence is for the biomarker-level claim: multiple randomized trials confirm that oral NMN and NR raise blood NAD+ in humans at 250–1,000 mg/day, with meta-analytic support for modest effects on glucose and lipid metabolism, and specific signals in insulin sensitivity, aerobic capacity, and arterial stiffness. The gap is that no human trial has measured lifespan, cardiovascular events, or cancer incidence as a primary endpoint — the dramatic lifespan and healthspan findings in mice have not been replicated in humans. NMN's US regulatory status is also contested after the FDA's 2022 communication that it may not lawfully be sold as a supplement, while NR has a cleaner GRAS history. Overall: real biomarker effects, genuine mechanistic rationale, but hard clinical outcomes remain aspirational rather than demonstrated.
History & Discovery
Before any of this is usefully discussed, a caveat: NMN and NR are not peptides. They are small-molecule nucleotide/vitamin B3 derivatives that feed into NAD+ biosynthesis. They appear on this site because the longevity community routinely discusses them alongside peptides like epithalon and MOTS-c, and users searching for a trusted peptide resource expect to find honest treatment of them. Treating them as peptides would be inaccurate; omitting them would be unhelpful. Nicotinamide riboside was identified as a distinct NAD+ precursor in yeast by Charles Brenner's group (then at Dartmouth, later Iowa) in 2004, building on decades of earlier niacin biochemistry. ChromaDex subsequently licensed NR chemistry and commercialized it as Niagen, and the compound has a relatively developed GRAS (generally recognized as safe) history in the US. Nicotinamide mononucleotide's popularization is largely associated with David Sinclair's Harvard lab, which pushed it as a more direct NAD+ precursor that crosses a specific cellular transporter (Slc12a8) — though the physiological importance of that transporter in humans remains debated. NMN's US regulatory status is contested: in 2022, the FDA informed industry that NMN had been investigated as a drug prior to being marketed as a supplement, meaning it may not lawfully be sold as a dietary supplement under current statute, though enforcement has been limited and the situation remains in flux. Human trial programs have so far been dominated by short-term biomarker endpoints — NAD+ levels, insulin sensitivity, aerobic capacity, arterial stiffness — run by groups including Brenner, Doug Seals and Chris Martens (Colorado), Shin-ichiro Imai (Washington University), and Morris (UK). There are currently no completed randomized trials in humans powered to detect lifespan or hard clinical endpoints.
How It Works
NAD+ is the fuel your cells need for energy production and repair. Levels drop as you age. NMN and NR are building blocks that your body converts into NAD+, potentially restoring more youthful cellular function.
NMN is converted to NAD+ by NMNAT enzymes. NR is first phosphorylated to NMN by NRK1/2, then converted to NAD+. NAD+ serves as a substrate for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38 (immune signaling). Sirtuin activation promotes mitochondrial biogenesis, autophagy, and stress resistance. NAD+ decline with age is driven by increased CD38 expression and PARP activation from accumulated DNA damage. Supplementation aims to outpace consumption and restore the NAD+/NADH ratio.
Evidence Snapshot
Human Clinical Evidence
Substantial and growing. Multiple randomized controlled trials confirm oral NMN and NR safely raise blood NAD+ levels. Meta-analyses show effects on glucose/lipid metabolism. Clinical trials in specific conditions (Parkinson's, cognitive impairment, peripheral artery disease, Werner syndrome) are underway or completed.
Animal / Preclinical
Strong. Dramatic lifespan and healthspan improvements in mouse models with NAD+ restoration.
Mechanistic Rationale
Very strong. NAD+ biology, sirtuin function, and age-related NAD+ decline are well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about NAD+ Precursors (NMN/NR):
- 01Lifespan and hard clinical endpoints — no human trial has measured all-cause mortality, cardiovascular events, or cancer incidence as primary outcomes. All published human evidence is biomarker-level.
- 02Tissue-level NAD+ distribution — blood NAD+ rises reliably with oral precursors, but whether critical tissues (brain, skeletal muscle, specific cardiac tissue) increase NAD+ proportionally in humans is incompletely mapped.
- 03NMN vs. NR head-to-head — direct comparisons at equivalent molar doses with matched endpoints are still limited; a 2026 comparison suggested differential effects on circulatory NAD+ and gut microbial metabolism, but the field has not converged on 'one is better.'
- 04Optimal dosing — the dose-response curve for biomarker effects appears to plateau, but the dose-response for clinical endpoints is unknown. Whether 250 mg/day is materially different from 1,000 mg/day for long-term outcomes is not established.
- 05IV NAD+ evidence base — the commercial practice of high-dose IV NAD+ has outpaced controlled clinical evidence; basic human PK, safety-at-scale, and comparative effectiveness data relative to oral precursors are underdeveloped.
- 06Long-term safety in special populations — older adults, individuals with metabolic disease, and those with subclinical malignancy have not been systematically followed over years of use.
Forms & Administration
Oral capsules or powder (most common). NMN: 250-1000mg/day. NR: 300-1000mg/day. Sublingual and IV NAD+ infusions are also available but less common.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Most human trials have used oral NR at 100–1,000 mg/day (commonly 300–500 mg) and oral NMN at 250–1,000 mg/day (commonly 500 mg). Both have shown dose-dependent increases in blood NAD+ within these ranges, with diminishing returns at the upper end. IV NAD+ infusions are offered in the wellness clinic space at 500–1,500 mg per session, but published human pharmacokinetic work on IV NAD+ remains thin and the practice has outrun the evidence base.
Frequency
Both NR and NMN are typically taken once daily. Morning administration with or without food is the most common pattern in the clinical trial literature, though evidence for meaningful circadian-timing effects in humans is limited. Split dosing (twice daily) is sometimes used at higher total daily doses to reduce GI side effects.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
These are generally taken continuously rather than cycled. Human trials have run up to 12 months (NMN in Japanese middle-aged men; NR in multiple cohorts) without tolerance or clear safety signals emerging at standard doses.
Protocol Notes
Oral bioavailability is established for both compounds. NR is absorbed and converted efficiently in the liver; NMN is absorbed intact in humans per pharmacokinetic studies, though the precise tissue distribution and whether systemic NMN reaches target tissues as NMN versus as downstream metabolites (nicotinamide, NR) is still being characterized. IV NAD+ deserves separate treatment. The practice — sometimes marketed as an 'anti-aging infusion,' sometimes in addiction-recovery contexts — uses NAD+ itself rather than a precursor, typically at doses far above what oral precursors can deliver. Clinical evidence for IV NAD+ is sparse relative to its commercial popularity, infusion-related side effects (chest pressure, flushing, nausea) are common and dose-rate-dependent, and the cost-per-intervention is high. For routine supplementation in people without a clinical indication, oral precursors have the better evidence-to-cost profile. Brand matters more here than with some supplements. NR sold as Niagen has a relatively clean manufacturing and GRAS history. NMN quality has been more variable, with third-party testing occasionally finding off-label content in consumer products. Buyers who care about what they are taking should look for third-party certificates of analysis.
These compounds are marketed as dietary supplements rather than approved drugs. Evidence for biomarker effects is reasonable; evidence for lifespan extension or prevention of age-related disease in humans is not yet established. Individuals with active or recent malignancy should discuss NAD+ precursor use with their oncologist before starting.
Timeline of Effects
Onset
Blood NAD+ levels rise within days of starting oral NR or NMN at standard doses, typically plateauing at 2–4 weeks. Subjective effects — where users report them — are most commonly described in the 2–6 week range and focus on energy, sleep quality, or recovery; these are self-reports and have not been consistently replicated in blinded trials.
Peak Effect
Human trials measuring peak NAD+ effects have most often found a plateau by 4–8 weeks of daily dosing. Some metabolic endpoints (insulin sensitivity in prediabetic women, aerobic capacity in amateur runners) have emerged over 6–10 weeks in the published trials. Whether effects continue to build beyond 3 months is not well characterized.
After Discontinuation
Blood NAD+ levels return toward baseline within 1–2 weeks of stopping supplementation in most published pharmacokinetic work. Any metabolic effects that depended on sustained NAD+ elevation would be expected to recede on a similar timescale. There is no well-documented rebound or withdrawal effect.
Common Questions
Who NAD+ Precursors (NMN/NR) Is NOT For
- •Active or recent-history cancer — any intervention that increases cellular NAD+ has a theoretical potential to support the metabolic demands of rapidly dividing cells. Patients with active malignancy should discuss with oncology before starting.
- •Pregnancy and breastfeeding — no adequate human safety data; standard guidance applies of avoiding non-essential supplementation during pregnancy and lactation.
- •Pediatric use — not studied in children; no established indication.
- •Uncontrolled gout or high baseline uric acid — nicotinamide metabolism can elevate methylation demand and, indirectly, uric acid in susceptible individuals; worth monitoring.
- •Known hypersensitivity to niacinamide or related compounds — rare but documented.
Drug & Supplement Interactions
Clinically significant drug interactions are uncommon at standard supplement doses, but several theoretical and observed considerations are worth naming. Methyl-donor balance: NAD+ precursor supplementation increases nicotinamide load, which is methylated by the enzyme NNMT using S-adenosylmethionine as a methyl donor. Some practitioners counsel co-supplementation with methyl donors (trimethylglycine, methylfolate) at high NAD+ precursor doses, though the clinical relevance in otherwise well-nourished individuals is debated. Anti-angiogenic or anti-cancer therapies: as noted under contraindications, raising NAD+ in the context of active cancer treatment may interact with mechanisms of action of various chemotherapeutic or targeted agents. This is a theoretical concern rather than a well-documented interaction. Statins, SSRIs, antihypertensives, and other common chronic medications: no consistent clinically significant interaction has been reported at standard supplementation doses. IV NAD+ has a separate interaction profile driven largely by infusion-rate side effects (flushing, chest pressure) rather than pharmacological interactions per se.
Safety Profile
Common Side Effects
Cautions
- • Long-term effects of supraphysiological NAD+ levels unknown
- • Theoretical concern about fueling cancer cell metabolism
- • Quality varies between supplement brands
What We Don't Know
Whether raising NAD+ levels translates to meaningful lifespan extension in humans is unproven. Long-term safety of chronic supplementation needs more study.
Legal Status
United States
Nicotinamide riboside is sold as a dietary supplement in the US, with a relatively established GRAS history (Niagen holds multiple GRAS affirmations). NMN's regulatory status is contested: in late 2022 the FDA communicated to industry that NMN had been authorized for investigation as a drug prior to being marketed as a supplement, potentially making it ineligible under the exclusionary clause of the Federal Food, Drug, and Cosmetic Act to be sold as a dietary supplement. Enforcement has been inconsistent, and NMN remains widely available, but the regulatory posture is unsettled and could change. Neither compound is a controlled substance.
International
Both NR and NMN are available as supplements in most jurisdictions. Specific product-registration requirements vary; the EU has a Novel Food framework under which some NAD+ precursor products have pursued or received authorization. Japan has been a particularly active market for NMN, which has accelerated clinical research there.
Sports & Competition
NR and NMN are not prohibited by WADA and are not on the USADA, UKAD, or other major sports-anti-doping prohibited lists. Routine supplementation is permitted for competitive athletes, though athletes should always check batch-level product purity because supplement contamination is a recurring source of positive tests.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
NMN and NR are peptides.
Reality
They are not. Both are small-molecule NAD+ precursors — nicotinamide-based nucleotides/nucleosides. This site covers them because users searching for peptide-adjacent longevity content expect to find them, but treating them as peptides misrepresents their chemistry.
Myth
Raising NAD+ extends human lifespan.
Reality
Mouse studies show healthspan and some lifespan benefits from NAD+ restoration. Human trials show NAD+ rises and some biomarker improvements, but no human trial has demonstrated lifespan extension or prevention of age-related disease as a hard outcome. Assuming biomarker gains translate directly to years of life is speculative.
Myth
NMN is clearly superior to NR because it is 'one step closer' to NAD+.
Reality
Being a downstream precursor does not automatically translate to better human tissue delivery or clinical effect. Both raise blood NAD+ at comparable oral doses. NR has more human clinical trial data. NMN has different absorption pathways and contested US regulatory status. The honest answer is that the head-to-head evidence has not converged.
Myth
IV NAD+ is dramatically more effective than oral NMN or NR.
Reality
IV NAD+ delivers higher acute blood levels than oral precursors, but the controlled-trial evidence base for IV NAD+ on clinical endpoints in humans is sparse relative to its price and promotion. Oral precursors are better supported per dollar spent.
Myth
NMN is FDA-approved as a dietary supplement.
Reality
FDA communicated in 2022 that NMN had been authorized for investigation as a drug before being marketed as a supplement, potentially excluding it from lawful sale as a supplement under the exclusionary clause. The regulatory posture remains unsettled. NR, in contrast, has a cleaner GRAS history.
Published Research
21 studiesNAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence
The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans
Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial
Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
What is really known about the effects of nicotinamide riboside supplementation in humans
NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin
The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects
The role of NAD and NAD precursors on longevity and lifespan modulation in the budding yeast, Saccharomyces cerevisiae
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
The Science Behind NMN–A Stable, Reliable NAD+Activator and Anti-Aging Molecule
Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men
Implications of altered NAD metabolism in metabolic disorders
Popular Stacks Including NAD+ Precursors (NMN/NR)
Quick Facts
- Class
- Nucleotide/Vitamin B3 Derivative
- Tier
- B
- Evidence
- Moderate
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 21PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.